Menu
+
+
+
+
+
+
FDA accepted and granted Priority Review to a BLA from Genentech Inc. for trastuzumab emtansine ( T-DM1) to treat HER2-positive, unresectable locally advanced or metastatic breast cancer in patients who have received...
BioCentury employs a fully integrated multimedia platform — including publications, video, online data solutions and conferences — to provide its audience with authoritative and up-to-date intelligence about corporate strategy, partnering, emerging technology, clinical data, public policy and the financial markets.
